Table 1 Top 5 pathways enriched by FunRich 3.0. In comparing controls (CTRL) vs Low-garde (LG) and High-grade dysplasia (HG) and pancreatic carcinoma (CAR), the following pathways were found to be enriched. The pathways are given in the order of their degree of enrichment from top to bottom in every column. HM means highest mean
1. CTRL VS LG | 2. CTRL VS HG | 3. CTRL VS CAR | |||
|---|---|---|---|---|---|
1A. HMCTRL | 1B. HMLG | 2A. HMCTRL | 2B. HMHG | 3A. HMCTRL | 3B. HMCAR |
1A1.Hemostasis | 1B1.Integrin family cell surface interactions | 2A1.Formation of Fibrin Clot (Clotting Cascade) | 2B1.Complement cascade | 3A1.Hemostasis | 3B1.Complement cascade |
1A2.Platelet activation, signaling and aggregation | 1B2.Beta1 integrin cell surface interactions | 2A2.Hemostasis | 2B2.Initial triggering of complement | 3A2.Complement cascade | 3B2.Formation of Fibrin Clot (Clotting Cascade) |
1A3.Initial triggering of complement | 1B3.Proteoglycan syndecan-mediated signaling events | 2A3.Initial triggering of complement | 2B3.Innate Immune System | 3A3.Initial triggering of complement | 3B3.Initial triggering of complement |
1A4.Intrinsic Pathway | 1B4.Alpha9 beta1 integrin signaling events | 2A4.Complement cascade | 2B4.Formation of Fibrin Clot (Clotting Cascade) | 3A4.Formation of Fibrin Clot (Clotting Cascade) | 3B4.Intrinsic Pathway |
1A5.Complement cascade | 1B5.Glypican pathway | 2A5.Intrinsic Pathway | 2B5.Terminal pathway of complement | 3A5.Intrinsic Pathway | 3B5.Innate Immune System |